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Sunrise for melanoma therapy – but early detection remains in the shade 
 
Melanoma is one of the most dangerous forms of cancer. The five-year survival rate is 98% if it is 
detected early. However, this rate plummets to 63% for regional disease and 17% when tumors have 
metastasized, that is, spread to distant sites. Furthermore, the incidence of melanoma has been rising 
by about 3% per year, whereas the incidence of cancers that are more common is decreasing. A 
handful of targeted therapies have recently become available that have finally shown real promise for 
treatment, but for reasons that remain unclear only a fraction of patients respond long term. These 
drugs often increase survival by only a few months in metastatic patient groups before relapse 
occurs. More effective treatment may be possible if a diagnosis can be made when the tumor burden 
is still low. Here, an overview of the current state-of-the-art is provided along with an argument for 
newer technologies towards early point-of-care diagnosis of melanoma.    
 
Melanoma facts and figures 
Skin darkens when epidermal melanocytes, a specific type of skin cell that is phenotypically different 
from other cells in the skin, release a dark brown pigment called melanin in the top layer of the skin 
in response to ultraviolet (UV) light. Nature uses melanin production as a protection mechanism 
against sun exposure to minimize UV light-induced damage to genetic material (DNA). In addition, 
skin cells have evolved complex biochemical repair systems to repair potential damage to their 
DNA. Unfortunately, excess damage can lead to the incorporation of oncogenic (cancer-causing) 
mutations that result in neoplastic transformation of benign melanocytes into malignant melanoma. 
Most melanoma originates within the skin, but because melanocytes also reside in other tissues, 
melanoma can originate in other locations such as the eye (uveal melanoma), which is exceptionally 
difficult to treat.  
Indeed, melanoma is one of most dangerous forms of cancer in general, and skin cancer in 
particular. Even though melanoma only accounts for about 1% of total skin cancers, it is responsible 
for almost 75% of total skin cancer deaths. Major risk factors for melanoma such as unusually high 
numbers of moles, fair skin and/or red hair, a family history of skin cancer, and sun burns are 
generally well established. Unfortunately, these risk factors are often ignored as the popularity of 
tanning and recreational activities in sunny destinations without proper use of UV protection 
continue to rise. This has resulted in a disturbing trend where, in contrast to several other cancer 
types whose numbers are steady or decreasing (e.g., lung cancer), the incidence rate of melanoma has 
been increasing for over three decades, at about 2.8% per year.  
In 2016 in the US alone, an estimated1 76,380 new cases of melanoma will be diagnosed and 
10,130 patients will die from this disease. Worldwide, there are an estimated 160,000 new melanoma 
patients and 48,000 deaths. The lifetime risk of developing melanoma in men is currently 1:39, and 
in women 1:63. In 1930, this number was around 1:1,500. Melanoma is the most common form of 
cancer for young adults 25-29 years old and the second most common form of cancer for 
adolescents and young adults 15-29 years old. It is the primary cancer that causes death among 
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women aged 20-25 years, while only trailing breast cancer in 30-35 year old women. These numbers 
indicate that melanoma has become an increasingly urgent public health issue. This is not likely 
going to become less of a problem in the foreseeable future, not only from a clinical perspective, but 
also economically because the high cost of typically failing metastatic melanoma patient therapy 
significant taxes an already overburdened health care system.  
Visual diagnosis: An inexact science  
Focusing on skin, the most commonly used mnemonic2 to diagnose a suspicious mole (also known 
as a nevus) as a potential melanoma is the so-called “ABCD”. A stands for Asymmetry, because the 
typical shape of a mole gets lost and one half is different from the other. B stands for Border 
Irregularity because the edges are often uneven. C stands for Color because rather than a uniform 
shade of brown, a melanoma may consist of a mix of brown, black and tan areas. Finally, D stands 
for a Diameter over 6 mm because larger moles are more likely to be malignant than small ones. E is 
sometimes added for Enlarging or Evolving, indicative of a growing population of potentially 
cancerous cells. Warning signs other than those listed in the ABCD/E include changes in sensitivity 
or bleeding. When a patient with a suspicious mole sees a doctor, typically a punch biopsy is ordered 
and the pathologist will diagnose based on histological and immunohistochemical markers. If the 
diagnosis is confirmed as melanoma, the tumor will be staged according to the criteria shown in 
Table 1. 
 
Table 1.  Melanoma staging and five-year survival rates 
 
Stage 0:  Melanoma in situ. In majority of cases, these tumors can be easily resected and five-
year survival rates are 99.9%. 
Stage I / II:  Invasive melanoma. These comprise smaller tumors (< 1 mm) with or without 
ulceration, or larger (< up to 2 mm) without ulceration. Five-year survival rates are 
89–95%.  
Stage II:  High risk invasive melanoma. A group of tumors ranging in size from 1.01- 4 mm in 
thickness further subdivided pending absence or presence of ulceration. Five-year 
survival rates are 45–79%.  
Stage III:  Local or regional metastasis. This entails involvement of up to four positive lymph 
nodes. Five-year survival rate is 24–70% with progressively worse prognosis if more 
lymph nodes have presence of tumor, or if a single lymph node is positive in 
combination with regional or skin metastases. 
Stage IV:  Distant metastasis showing widespread disseminated disease and organ involvement. 
Further sub-classification takes lung metastasis and lactate dehydrogenase (LDH) 
levels into account, with overall poor five-year survival rates of 7–19%.  
 Of critical prognostic importance are the assigned "Clark level" and "Breslow's depth", 
which refer to the vertical rather than horizontal growth phase of the tumor. In the absence of any 
other reliable biomarkers, this is one of the best clinical predictors of metastasis.  
Unfortunately, the “ABCD/E” technique has many problems. Multiple types of melanoma 
are recognized but not all of these can be detected by “ABCD/E”. Furthermore, many melanomas 
will not display all four or five characteristics simultaneously. This poses a big challenge for the 
correct diagnosis of the estimated 60-70 million moles that are screened annually. In the absence of 
more specific non-invasive tests, about 10% of these suspicious moles are excised but only 3% are 
actually cancerous moles. In other words, 97% or almost all of the 6-7 million excised moles each 
year are unnecessarily removed.  
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Emerging non-invasive technologies to diagnose suspicious skin moles 
Several companies have realized that a diagnostic test that can differentiate between a mole that is 
malignant and one that is atypical, but otherwise benign, can be of great clinical and commercial 
importance. The market size for screening moles is $2-$3B per year and that of subsequent analysis 
of biopsies is about $400M. Four leading technologies that address this issue are listed in Table 2. 
Furthest regulatory development has been achieved for MelaFind and Symsys Molemate, which are 
the only two technologies to have received recent FDA marketing approval. MelaFind uses light to 
differentiate benign from malignant moles based on their specific absorption profiles while Symsys-
Molemate employs intracutaneous spectrophotometry to analyze vascular composition and 
pigmentation. In a somewhat analogous fashion, NeviSense and Aura use the inherent differences in 
electrical impedance and Raman spectra, respectively, between normal and malignant nevi to 
correctly identify only those lesions that must be removed. All four devices are designed to be used 
in a point-of-care (POC) setting to support and advise rather than replace the pathologist’s 
assessments, and thereby reduce the number of unnecessary excisions. However, it is noteworthy 
that even MelaFind is far from being accepted, let alone adopted by the medical establishment due 
to its heavy bias towards (false) positive identification of malignancy. Furthermore, the devices can 
only be used on moles of certain sizes and degree of pigmentation, such that the anatomical location 
and lesion condition (e.g., scarring, ulceration) of a mole can further restrict their usage. An 
alternative type of technology is being developed by DermTech based on genetic markers for 
melanoma. Suspicious cells are lifted from the lesion by adhesive tape and the RNA expression 
profile is obtained by quantitative polymerase chain reaction (qPCR) techniques and compared to a 
proprietary panel of melanoma-associated genes to correctly diagnose the mole. Claimed sensitivity 
and specificity of this technology is extremely high. However, it is not a POC technology, validation 
is still ongoing, and the FDA approval date is uncertain. 
These technologies still require varying levels of refinement. However, it is encouraging that 
considerable advances have been made to aid the pathologist in reaching a correct diagnosis of skin 
lesions, which is currently done with < 20% accuracy. It is conceivable that at least one of these 
technologies will eventually become part of the standard of care with clear benefits for the payer and 
the patient. However, it is important to note that while these diagnostic devices prevent many 
unnecessary biopsies, they do not impact treatment or survival of metastatic melanoma patients. 
 
New therapies provide hope to metastatic melanoma patients within limits 
Conventional treatments for melanoma are surgery (very successful in early stage melanoma), 
radiotherapy, chemotherapy (e.g., dacarbazine), and immunotherapy. The latter essentially consisted 
of use of interferon alfa-2B, a formulation that was improved upon in 2011 by a pegylated version 
(Sylatron). All of these treatments are nevertheless essentially helpless against metastatic melanoma, 
a situation that has remained unchanged until in 2011 the first of 6 new targeted therapies presented 
advanced stage disease patients with exciting benefits (Table 3). Even though, in absolute terms the 
effects on survival are relatively small, on the order of 3-6 months due to invariably occurring 
resistance and relapse of the patients, a large percentage of patients respond significantly to the 
drugs, something that was never before seen in metastatic melanoma on this scale. The first 
approved immunotherapeutic drug is Yervoy, an antibody that targets and inhibits CTLA-4, a 
negative regulator of cytotoxic T-cell activity that is critical for mounting an effective antitumor 
immune response. Using a similar strategy, two other antibodies, named Keytruda and Opdivo, 
block the interaction of PD-1 on T-cells with its ligands PD-L1 and PD-L2 to reactivate antitumor 
immunity in melanoma and other cancer types. This mechanism received “Breakthrough Therapy” 
status from the FDA. 
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Table 2.  The most advanced non-invasive technologies for diagnosis of skin moles 
 
Trade name  Technology and Advantages/Disadvantages 
 
 
HAND HELD OPTICAL SCANNING DEVICES 
MELAFIND - Developed by MELA Sciences (US), POC device uses light to image the skin 
through a layer of isopropyl alcohol to generate a positive or a negative result 
based on predefined image analysis algorithms. Sensitivity is 98.3% and 
specificity 10.8%. FDA approved on November 2011. 
 - Not covered by health insurance.  
 - Usefulness heavily debated due to engineered bias towards positive results, 
thus negating its intended advantage over traditional pathology exams. 
 
NEVISENSE  - Developed by SciBase (Sweden), POC device uses electric impedance 
spectroscopy to determine if a mole is benign or malignant melanoma with 
claimed 97% sensitivity and 34% specificity.  
 - FDA approval has not yet been obtained although device was approved in 
Australia in October 2013. 
 
AURA - Developed by Verisante Technology (Canada), POC device uses Raman 
spectroscopy to measure differential vibrational modes of biomolecules 
between benign and melanoma skin lesions. At a sensitivity level of 90-99%, 
positive predicted values were between 15-30% and negative predicted values 
were at 98-99%. 
 - Approved by Health Canada as Class II Device in 2011, but FDA approval 
has not yet been obtained. 
 
SIMSYS- - Developed by MedX Health (Canada), POC device uses spectrophotometric 
MOLEMATE intracutaneous analysis to image and analyze vascular composition and melanin 
of suspicious skin lesions. 
 - Approved by FDA in September 2011, by Health Canada as Class II Device 
in January 2012, and can also be marketed in Europe. 
 - Wide applicability not limited to melanoma. 
 - A UK study showed that the device operates at a cost of £18 over best 
practice and only adds 0.01 quality-adjusted life-year per patient. Moreover, use 
of MoleMate resulted in more referrals and evidence suggests that best practice 
is still more accurate. 
 
OTHER TECHNOLOGIES 
PIGMENTED  - Developed by DermTech (US), skin cells from a mole are lifted using  
LESION ASSAY a proprietary Adhesive Skin Biopsy Kit. Next, a qPCR-based assay analyzes 
RNA expression profiles of these cells to determine if they are associated with 
melanoma or non-melanoma. Claimed accuracy is 91%, with 91% sensitivity 
and 69% specificity. 
 - Complex analysis is not suitable for POC. 
 - FDA approval date is unknown. 
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  Distinct from antibody-based strategies are a new generation of targeted small molecules, of 
which Zelboraf (vemurafenib) was the first to be approved. About half of all melanomas have a 
mutation in the BRAF gene resulting in a permanently active form of BRAF called BRAFV600E or 
BRAFV600K. BRAF is a signaling molecule that helps tumor cells proliferate. Zelboraf inhibits the 
mutated BRAF forms in the tumor cells and has been shown to shrink many of these tumors. 
Zelboraf, and similarly designed Tafinlar (dabrafenib) are now used in melanomas that test positive 
for the BRAFV600E gene change in companion diagnostic assays. Finally, Mekinist (trametinib) targets 
a downstream effector of BRAF called MEK. Mekinist is approved for treatment of tumors that 
carry either the BRAFV600E or BRAFV600K mutation, which is also determined by a PCR-based 
companion diagnostic test.  
 
Table 3.  Recently approved therapies in (metastatic) melanoma 
 
Trade name (USAN)  Approval date Manufacturer Drug target  
 
Sylatron (peginterferon-alfa-2B)  March 29, 2011 Schering Immunomodulatory  
   genes 
 
YERVOY (ipilimumab) March 25, 2011 Bristol-Myers Squibb CTLA-4 
 
KEYTRUDA (pembrolizumab) September 4, 2014 Merck PD-1 
 
OPDIVO (nivolumab) December 22, 2014Bristol-Myers Squibb PD-L1 
 
ZELBORAF (vemurafenib) August 17, 2011 Genentech/Roche BRAFV600E 
 
TAFINLAR (dabrafenib) May 29, 2013 GlaxoSmithKline BRAFV600E 
 
MEKINIST (trametinib) May 29, 2013 GlaxoSmithKline  MEK 
 
 
There are indications that, once durable responses are achieved, patients may remain disease free. 
However, as promising as these results may be, there remains a huge unmet clinical need for 
therapeutics that can achieve longer lasting responses in the majority of patients.  
Alternatively, a diagnostic test that can detect early-stage metastatic disease by measuring the 
presence of melanoma biomarkers or circulating melanoma cells (CMCs) in the bloodstream before 
the cells colonize distant organs may dramatically impact long-term survival in this patient group. It 
is conceivable that when the tumor burden is low, melanoma cells may be more responsive to 
(chemo)therapy because less time has been available for potentially resistant genetic variants to 
develop. This paradigm has never been tested, because technologies that can reliably detect very 
small numbers of circulating or metastasized melanoma cells are extremely limited in their capacities 
and reliable biomarkers are not currently known to exist in blood. However, new technologies are 
being developed, which, combined with new biomarker discoveries, may change this situation. 
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Quantifying circulating tumor cells as a prognostic tool 
When cancer cells detach from the primary tumor and enter the bloodstream, they can circulate 
through the body and invade distant organs, a process known as metastasis. Metastasis is the typical 
cause of death for a cancer patient. Circulating tumor cells (CTCs) have been detected in a variety of 
carcinomas and they appear at widely varying frequencies. The hypothesis that is supported by a 
number of clinical studies is that the number of CTCs is associated with reduced progression-free 
and overall survival. As such, a device that can quantify CTCs can be used as an early warning 
prognostic tool when more conventional imaging technologies are not adequately sensitive. Direct 
detection of CTCs is technically very demanding because their typical presence is only 1-10 CTCs 
per 106 (1-10 parts per million) blood cells. Numerous technical strategies have been evaluated for 
the direct detection of CTCs, but there are only two viable technologies, as discussed below. 
PCR. PCR is an extremely sensitive technique for detecting the presence of minute quantities of 
genetic material (RNA or DNA). PCR has been hypothesized to be able to detect melanoma-
associated RNA as a marker for CMCs. In 1998, the University of Chicago began a trial with the 
NCI (NCT00004153). The goal was to determine if performing nested reverse transcriptase-PCR 
(RT-PCR) on a panel of five different melanoma-associated genes to increase sensitivity and 
specificity over single gene analysis, using lymph node samples or peripheral blood from melanoma 
patients, could predict relapse and disease stage. 106 patients were enrolled and followed for two 
years, and the study was completed in 2005. Unfortunately, the RT-PCR-based analysis suffered 
from inherent major technical issues and no study results were ever reported on ClinicalTrials.Gov. 
Additional PCR-based clinical studies have shown that the correlation of increasing numbers of 
CMCs and worse disease stage and prognosis is generally correct, but not perfect. Moreover, the 
PCR-based approaches remain technically troublesome. A promising variant of this approach was 
presented by Dundee University (UK) researchers, who claimed that levels of TFP12 DNA in 
patient blood could be a key marker to correctly predict disease progression; however, these studies 
still need validation in larger clinical trials. 
CellSearch System. CellSearch System is a device marketed by Veridex (US). This technology uses 
antibodies that selectively adhere to a specific molecule type on the CTC surface, for example 
EpCam in case of epithelial tumors. Once the antibody attaches to its target, the CTCs are separated 
from the blood cells by directing them into different microfluidic channels. The claimed analytical 
sensitivity is 1 CTC/7.5 mL blood (or 1 CTC per 40 billion blood cells) with a specificity of 99.7%. 
The device was first developed for use in breast cancer where patients with >5 CTCs/7.5 ml blood 
were found to have a considerably worse outlook than those with <5 CTCs/7.5 ml. The FDA 
approved the CellSearch System to predict progression-free survival (PFS) and overall survival (OS) 
in patients with metastatic breast cancer, which was subsequently expanded on March 8, 2008 to 
include colorectal and prostate cancer. The CellSearch System is also available in Europe. Similar to 
CellSearch, the Maintrac CTC Count Test uses fluorescence-based enumeration of Circulating 
Epithelial Tumor Cells (CETC) through quantitative microscopic analysis of epithelial cells 
expressing Epcam that are bound by FITC-conjugated anti-CD45 antibodies. Unfortunately these 
devices have significant drawbacks. For instance, not all epithelial tumor cells express Epcam, which 
would confound any interpretations based on set critical number limits. A 3rd generation CTC-iChip 
is now being developed at Massachusetts General Hospital (US). It plans to address the issue by 
using magnetic beads and filtration to actively remove the blood cells. Furthermore, melanoma is 
not an epithelial cancer, therefore it requires targeting of melanoma-specific cell surface proteins. 
This requires extensive R&D and clinical validations of candidate biomarkers, as the long-term 
viability of the CellSearch System has already been questioned by some analysts.  
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Surrogate biomarkers for the detection of early stage melanoma:  
Novel biomarker TROY 
In light of the many technical issues associated with detection of CMCs, a large number of secreted 
or shed serum factors have been analyzed as potential surrogate diagnostic and/or prognostic 
biomarkers. Unfortunately, they also suffer from reliability and/or sensitivity problems that prevent 
their use in a clinical setting. These include today’s most widely-used melanoma 
immunohistochemical biomarkers S100b, HMB-45 and MART-1.3,4 Therefore, there is no gold 
standard or imminent technology with the capability of detecting occult metastatic melanoma in 
blood either directly or indirectly. However, a new candidate melanoma biomarker has recently been 
discovered, which, in combination with a novel ultrasensitive point-of-care detection technology, 
may address this unmet need. 
 
TROY (TNFRSF19) is a type I orphan member of the tumor necrosis factor receptor superfamily 
(TNFRSF).5 It is ubiquitously expressed during embryonic development where it may control cell 
proliferation and inhibit differentiation6 through binding with lymphotoxin-alpha7 or perhaps an as-
yet-unidentified ligand.8 After birth, expression is restricted to hair follicles and the brain,9,10 where it 
functions as a inhibitory coreceptor of nerve cell regeneration.11,12 However, there is increasing 
evidence linking disregulation of TROY expression to human disease. TROY is upregulated in 
multiple sclerosis and spinal cord injury, suggesting a role in central nervous system pathologies.13 
TROY mRNA is overexpressed in advanced glial tumors and its elevated expression both correlates 
with a poor patient outcome and increases the migration and invasion capabilities of glioblastoma 
cell lines.14 TROY is expressed in all primary and metastatic melanoma cells, but not healthy 
melanocytes or other normal cells or tissues with the exception of sebaceous glands.15 Thus, TROY 
is an aberrantly re-expressed embryonic gene in melanoma. To our knowledge, it is the only 
melanoma-specific cell surface biomarker. Type I membrane receptors such as TNFR1 (which binds 
TNFalpha) and EGFR are known to shed their extracellular domain (ECD).16,17 The presence of 
melanoma-derived TROY ECD in patient serum would therefore present a unique opportunity for a 
diagnostic blood test as a surrogate marker for CMCs and occult metastasis. Additionally, when 
combined with an innovative sensor platform that performs ultrasensitive, real-time point-of-care 
measurements of shed TROY in ECD, such a test has the potential to change the standard of care. 
A possible melanoma treatment plan integrating this diagnostic technique is shown in Figure 1. 
 
Life-long monitoring of melanoma patients who have undergone therapy but are at risk of 
relapse for presence of CMCs. Distinct from diagnosis of new patients, there are additional uses 
of a TROY-based diagnostic test. Cure rates for melanoma never reach 100%. Even commonly 
diagnosed stage I/II patients already have a 5-11% chance of relapse. Relapse probabilities become 
worse as staging increases, indicating that in those cases there already is widespread, but 
undetectable (occult) metastatic disease. These at-risk patients that are clinically free of disease could 
be subjected to periodic testing by our CMC-detecting device. Patients with elevated levels could be 
treated immediately to prevent establishment of metastatic tumors in distant organs. Finally, TROY 
serum levels can be utilized as a read-out for the success of treatment of established metastatic 
melanoma patients. If TROY levels do not decrease, indicating resistance, an alternative therapeutic 
approach would be selected. This would be highly beneficial to the patient because it would reduce 
time spent on ineffective treatments with potential associated side effects, toxicity, and morbidity, 







Figure 1. The proposed diagram demonstrates the potential use for the TROY sensor in diagnosis and 
prognosis of melanoma. 
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Point-of-care diagnostic blood test for melanoma 
A Point-Of-Care (POC) diagnostic blood test that can detect abnormally elevated levels of TROY 
ECD as a direct read-out for the presence of CMCs and occult distant metastasis can revolutionize 
diagnosis and treatment of melanoma. The primary application for such a novel device is early 
detection of melanoma using the proposed blood test. Because no such diagnostics test exists in the 
market at this time, an estimated 400,000 patients may go undiagnosed every year. Not only is early 
diagnosis of these patients using a POC blood test expected to positively impact survival rate, the 
test can also be used for monitoring of therapy responsiveness and lifelong monitoring. 
There are numerous technologies capable of detecting protein markers in blood with the 
required sensitivity and specificity. However, these incumbent technologies can only be employed in 
a central laboratory setup. These methods used to measure (serum) protein levels are proteomic 
technologies, such as fluorescent imaging on microarrays, or they are conventional technologies like 
enzyme-linked immunosorbent assay (ELISA) that are not well suited for real-time, POC 
diagnostics.18 
 
Figure 2. Sensing of the melanoma biomarker TROY using FAB-functionalized nanowires. The conductance 
change of the nanowires in response to different concentrations of TROY in 2 mM PBS buffer (squares, 
circles and triangles) is compared to the response to BSA (stars) in the same buffer. A linear dependence 
between conductance change and concentration is observed in the 10 ng/ml to 1 µg/ml regime of TROY 
concentration. 
Among the scalable technologies that can be naturally incorporated into a low-cost handheld 
configuration for point-of-care use is the silicon-based semiconductor nanosensor. Figure 2 shows 
that this device has the required sensitivity for TROY detection19. The corresponding device, shown 
in Figure 3, is relatively cheap to manufacture, plus the nanosensor and microfluidics/electronics 
(Figure 3(c)) in a disposable cartridge configuration are well suited for a POC device. Unlike 




Figure 3. (Left) (a) Electrical nanowire sensors fabricated using e-beam lithography; (Right) (b) Single 
nanowire conductance channel 50 nm in width. (c) Instrument footprint showing chip carrier, and control 
electronics in the black box. 
These silicon nanochannel sensors, which have the ability to detect the presence of a 
biomarker by directly measuring the change in electric potential upon binding of antigen to an 
antibody conjugated to the sensor20,21,22, shown schematically in Figure 4(b) and 4(c), have 
demonstrated exciting potential as next-generation POC diagnostic devices. The great strides in 
semiconductor technology allow such sensors to be fabricated cheaply with excellent reproducibility 
as it has been demonstrated for the detection of breast cancer biomarker CA15.3.23 Electrical 
measurements can be configured to provide a simple, effective, and inexpensive method for 
melanoma biomarker sensing. The combination of state-of-the-art semiconductor nanotechnology 
and the emergence of a novel and unique melanoma biomarker translates to a first-in-class proof-of-
concept diagnostic device. 
 
Figure 4. (a) Electron micrograph of two separate sets of silicon nanowires with the electrical connections 
insulated from solution by a micrometer thick layer of poly(methyl methacrylate) (PMMA). (b) 
Immobilization of the antibody FAB to the silanized nanowire using NHS/EDC coupling chemistry. The 
FAB has one constant and one variable domain from each heavy and light chain of the antibody (constant 
heavy (CH), constant light (CL), variable heavy (VH) and variable light (VL). It binds with its C-terminal end 
to the nanowire exposing the paratope at its variable end to the solution. (c) The sensing nanowires are sealed 
in a fluid chamber with an inlet and outlet at opposing ends. Their conductance is tunable by a reference 
electrode immersed in the solution and a back gate connected to the bulk silicon.  
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Future outlook 
Metastatic melanoma is extremely difficult to treat because tumors are virtually resistant to any type 
of therapy. Results from the new generation of immunotherapeutic drugs have been impressive but 
they only appear to be effacious in a subset of patients and only temporarily halt tumor 
progression.24 A highly attractive, alternative strategy to reduce melanoma mortality is to determine 
the presence of melanoma cells before they become clinically detectable by conventional means such 
as PET-CT, when tumors already are too large and virtually incurable. When tumor cell numbers are 
low, they may be more sensitive to therapy. Until now, lack of a reliable melanoma biomarker(s) and 
accompanying ultrasensitive point-of-care diagnostic devices have made testing of this breakthrough 
concept impossible.  However, innovative technologies that build upon decades of advances in 
semiconductor fabrication and processing can now offer revolutionary potential for changing the 
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